Furthermore, the development of a tumor model using human MHC-I transgenic mice will allow us to test therapeutic HPV vaccines capable of generating CD8+ T cells against HPV antigen presented by the human MHC-I molecules by tumor cells. This evidence concerns the gene CD8A and neoplasm.